Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness.

Nathan RA, Minkwitz MC, Bonuccelli CM.

Ann Allergy Asthma Immunol. 1999 May;82(5):497-503.

PMID:
10353583
2.

Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma.

Kemp JP, Minkwitz MC, Bonuccelli CM, Warren MS.

Chest. 1999 Feb;115(2):336-42.

PMID:
10027429
3.

An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses.

Tashkin DP, Nathan RA, Howland WC, Minkwitz MC, Simonson SG, Bonuccelli CM.

J Allergy Clin Immunol. 1999 Feb;103(2 Pt 1):246-54.

PMID:
9949315
4.

Effectiveness and tolerability of zafirlukast for the treatment of asthma in children.

Pearlman DS, Lampl KL, Dowling PJ Jr, Miller CJ, Bonuccelli CM.

Clin Ther. 2000 Jun;22(6):732-47.

PMID:
10929920
5.

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.

Nathan RA, Bernstein JA, Bielory L, Bonuccelli CM, Calhoun WJ, Galant SP, Hanby LA, Kemp JP, Kylstra JW, Nayak AS, O'Connor JP, Schwartz HJ, Southern DL, Spector SL, Williams PV.

J Allergy Clin Immunol. 1998 Dec;102(6 Pt 1):935-42.

PMID:
9847434
6.

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group.

Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM.

Clin Ther. 1997 Jul-Aug;19(4):675-90.

PMID:
9377612
7.
8.

Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma.

Bousquet J, Aubert B, Bons J.

Ann Allergy Asthma Immunol. 1996 Feb;76(2):189-94.

PMID:
8595540
9.

A comparative study of the clinical efficacy of nedocromil sodium and placebo. How does cromolyn sodium compare as an active control treatment?

Schwartz HJ, Blumenthal M, Brady R, Braun S, Lockey R, Myers D, Mansfield L, Mullarkey M, Owens G, Ratner P, Repsher L, van As A.

Chest. 1996 Apr;109(4):945-52.

PMID:
8635375
10.

Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability.

Zhang J, Yu C, Noonan G, Reiss TF.

Clin Ther. 2002 Apr;24(4):574-82.

PMID:
12017402
12.

A controlled trial of twice daily triamcinolone oral inhaler in patients with mild-to-moderate asthma.

Ramsdell JW, Fish L, Graft D, Higgins N, Kavuru M, Pleskow W, Banerji D.

Ann Allergy Asthma Immunol. 1998 May;80(5):385-90.

PMID:
9609607
13.

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.

Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA.

J Allergy Clin Immunol. 1999 Jun;103(6):1075-80.

PMID:
10359889
14.

Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma : a placebo-controlled comparison.

Boonsawat W, Goryachkina L, Jacques L, Frith L.

Clin Drug Investig. 2008;28(2):101-11.

PMID:
18211118
16.
17.

Montelukast: a review of its therapeutic potential in persistent asthma.

Jarvis B, Markham A.

Drugs. 2000 Apr;59(4):891-928. Review.

PMID:
10804041
20.

Once-daily evening administration of mometasone furoate in asthma treatment initiation.

Bensch GW, Prenner B, Berkowitz R, Galant S, Ramsdell J, Lutsky B.

Ann Allergy Asthma Immunol. 2006 Apr;96(4):533-40.

PMID:
16680923

Supplemental Content

Support Center